Radiofrequency denervation of the renal arteries in patients with resistant arterial hypertension: 3 years of observation experience
https://doi.org/10.26442/2075082X.2019.4.190596
Abstract
Objective. To evaluate the efficiency of radiofrequency denervation of the renal arteries in patients with resi-stant arterial hypertension during a three-year follow-up. Materials and methods. The study involved 40 patients with resistant arterial hypertension aged 27 to 70 years (mean age 54.91±9.77 years) while receiving three or more antihypertensive drugs (including diuretic) in optimal doses. The conditions for inclusion in the study were considered resistant arterial hypertension with blood pressure (BP)>160/100 mm Hg, intact kidney function - glomerular filtration rate (MDRD)>45 ml/min - and the absence of secondary hypertension. All patients had sympatic radiofrequency denervation of renal arteries; its efficiency later was estimated according to the clinical measurement and ambulatory blood pressure monitoring (ABPM). Results. The level of office BP reliably differed initially and after 3 years: DSBP -34.48±6.44 mm Hg (p=0.001), DDBP - 22.29 mm Hg (p=0.001). According to ABPM results, reliable dynamics of systolic blood pressure was not observed. The data of DBP at night were significantly lower after 36 months; DDBP was -5.37±9.77 mm Hg. Conclusions. A marked decrease in the data of office SBP and DBP was observed, which proves the long-term efficiency of radiofrequency denervation of the renal arteries in patients with resistant hypertension. Accor-ding to ABPM results after 36 months, a significant decrease was registered among the DBP indicators at night and daytime.
About the Authors
N. Yu. Savelyeva
Tyumen Cardiology Research Center - branch of Tomsk National Research Medical Center
Russian Federation
Russian Federation
A. Yu. Zherzhova
Tyumen Cardiology Research Center - branch of Tomsk National Research Medical Center
Russian Federation
Russian Federation
E. V. Mikova
Tyumen Cardiology Research Center - branch of Tomsk National Research Medical Center
Russian Federation
Russian Federation
L. I. Gapon
Tyumen Cardiology Research Center - branch of Tomsk National Research Medical Center
Russian Federation
Russian Federation
G. V. Kolunin
Tyumen Cardiology Research Center - branch of Tomsk National Research Medical Center
Russian Federation
Russian Federation
D. V. Krinochkin
Tyumen Cardiology Research Center - branch of Tomsk National Research Medical Center
Russian Federation
Russian Federation
References
1. ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the mana-gement of arterial hypertension of the European Society of Cardiology (ESC) and the European So-ciety of Hypertension (ESH). Eur Heart J 2018.
2. Forouzanfar M.H, Liu P, Roth G.A еt al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA 2017; 317: 165-82.
3. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.
4. Gottesman R.F, Albert M.S, Alonso A et al. Associations between midlife vascular risk factors and 25- year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. JAMA Neurol 2017; 74: 1246-54.
5. Myat A, Redwood S.R, Qureshi A.C et al. Resistant hypertension. BMJ 2012; 345: e7473-7473.
6. Daugherty S.L, Powers J.D, Magid D.J et al. Incidence and prognosis of resistant hypertension in hy-pertensive patients. Circulation 2012; 125: 1635-42.
7. Pierdomenico S.D, Lapenna D, Bucci A et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005; 18: 1422-8.
8. Calhoun D.A, Jones D, Texto S et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51: 1403-19.
9. Чазова и.е., Фомин в.в., Разуваева м.а., Вигдорчик а.в. Резистентная и неконтролируемая артериальная гипертония в российской федерации: эпидемиологическая характеристика и подходы к лечению (Российский регистр неконтролируемой и резистентной артериальной гипертонии регата «резистентная гипертония артериальная»). Кардиологический вестн. 2011; vi (xviii): 40-8.
10. Rosenbaum D, Villeneuve F, Gury C, Girerd X. Frequency of hypertension resistant to treatment and indication for renal denervation. Annales de Cardiologie et d'Angeiologie 2012; 61: 229-35.
11. Gupta A.K, Nasothimiou E.G, Chang C.L et al. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. J Hyper-tens 2011; 29: 2004-13.
12. Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of resistant hy-pertension in treated hypertensive population. Am J Hypertension 2015; 3: 355-61.
13. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373 (9671): 1275-81. DOI: https://doi.org/10.1016/S0140-6736(09)60566-3
14. Esler M.D, Krum H, Sobotka P.A et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (the SYMPLICITY HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-9.
15. Личикаки В.Ф., Мордовин В.Ф., Пекарский С.Е. и др. Гипотензивня эффективность ренальной денервации и ее влияние на изменение степени выраженности гипертрофии левого желудочка. Сиб. мед. журн. 2016; 31 (2): 15-7.
16. Bhatt D.L, Kandzari D.E, O'Neill W.W et al. A Controlled Trial of Renal Denervation for Resistant Hyper-tension. N Engl J Med 2014; 370: 1393-401. DOI: 10.1056/NEJMoa1402670
17. Башта Д.И., Романов А.Б., Колесников В.Н. и др. Ренальная денервация - новые подходы в оптимизации гипотензивного эффекта. Мед. вестн. Северного Кавказа. 2017; 12 (4): 431-4. DOI: https://doi.org/10.14300/mnnc.2017.12121
18. Болотов П.А., Семитко С.П., Климов В.П., Верткина Н.В. Транскатетерная симпатическая денервация почек в лечении резистентной артериальной гипертензии: современное состояние вопроса. Consilium Medicum. 2018; 20 (5): 40-9.
19. Shishehbor M.H, Hammad T.A, Thomas G. Renal denervation: What happened, and why? Cleveland Clin J Med 2017; 84 (9): 681-6.
20. Григин В.А., Данилов Н.М., Сагайдак О.В. и др. Методы оценки симпатической активности у пациентов с рефрактерными к лечению системными гипертензиями. Системные гипертензии. 2014; 11 (4): 21-6.
21. Kandzari D.E, Kario K, Mahfoud F et al. The SPYRAL HTN Global Сlinical Trial Program: Rationale and design for studies of renal denervation in the absece (Spyral HTN OFF-Med) and presence (Spyral HTN ON-MED) of antihypertensive medications.
22. Resistant Hypertension: Detection, Evaluation, and Management. A Scientific Statement From the American Heart Association. Hypertension 2018; 72: e53-e90. DOI: 10.1161/HYP.0000000000000084
23. Mahfoud F, Bakris G, Bhatt D.L, et al. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. Eur Heart J 2016; 38 (2): 93-100. DOI: 10.1093/eurheartj/ehw325
24. Гапон Л.И., Микова Е.В., Савельева Н.Ю. и др. Гипотензивный эффект радиочастотной денервации почечных артерий у пациентов с резистентной артериальной гипертонией. Клиническая практика. 2017; 3: 25-31.
25. Кушхова Р.Р. Резистентная артериальная гипертензия: морфофункциональные изменения сердечно-сосудистой системы. Вестн. новых медицинских технологий. 2016; 23 (2): 148-52.
26. Глыбочко П.В., Светанкова А.А., Родионов А.В. и др. Ренальная денервация при резистентной артериальной гипертензии: результаты 5-летнего наблюдения. Терапевтический архив. 2018; 9: 88-91. DOI: 10.1430/mnnc.2017.12121
Review
For citations:
Savelyeva N.Yu., Zherzhova A.Yu., Mikova E.V., Gapon L.I., Kolunin G.V., Krinochkin D.V. Radiofrequency denervation of the renal arteries in patients with resistant arterial hypertension: 3 years of observation experience. Systemic Hypertension. 2019;16(4):65-69. (In Russ.) https://doi.org/10.26442/2075082X.2019.4.190596
Views:
99
Email this article 